L-257-2020
Agreement ID
L-257-2020
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
GeoVax, Inc.
Fiscal Year
2021
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2000 Recombinant Vaccines Based on Poxvirus Vectors
TAB-1589 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes
TAB-2068 Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines
TAB-3261 Prefusion Coronavirus Spike Proteins and Their Use
TAB-3532 Prefusion Coronavirus Spike Proteins and Their Use
TAB-1589 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes
TAB-2068 Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines
TAB-3261 Prefusion Coronavirus Spike Proteins and Their Use
TAB-3532 Prefusion Coronavirus Spike Proteins and Their Use